tirzepatide indication vs. Semaglutide: Which Weight Loss Medication is Right for You? Comparative safety and side effects
Description
Gastrointestinal adverse events, particularly nausea and diarrhea, are the most common side effects of tirzepatide, occurring in a dose-dependent manner
Listed on Oct 17, 2024 | Patient, Peptide therapy, Fat loss
Clinical trials show you could lose up to 22% of your body weight after 64 weeks
Reta (GLP-3) research product | Peptide Koning
Truveta Research shares a new study that explores GLP-1 reinitiation trends and factors following discontinuation.
An integrated approach providing wraparound care is needed to address the increase in GLP-1 use and to curb rising costs for many employers and health plans.
